FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 747 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR The director’s cut: How Dr Catherine Elliott sees the future of... November 2, 2021 It’s a fair COP: Why our chief clinician went to a... December 13, 2021 Wawa Employee Saves Life Of Customer Who Stopped Breathing After A... January 20, 2022 BooHoo Is Selling Bras With Subtle Patterns To Help You Check... October 26, 2019 Load more HOT NEWS Talking About Sexual Health Concerns With Your Cancer Care Team: How... Plant-Based Diets and a New Treatment Combination for Prostate Cancer: Research... What Are Social Determinants of Health and How Do They Affect... NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials
